Trial Updates Archives

Chemotherapy: the backbone of lymphoma treatment

VJHemOnc is excited to present the latest developments in the role of chemotherapy across lymphomas

The role of MRD in multiple myeloma

VJHemOnc is pleased to bring you a feature exploring the emerging applications of MRD in multiple myeloma.

Novel agents in MDS

VJHemOnc is pleased to bring you a feature exploring the latest advances and developments in novel agents for MDS, with…

MRD as a clinical and regulatory endpoint for AML

VJHemOnc is pleased to bring you a feature exploring the latest thinking on the application of MRD in AML trials…

Pirtobrutinib receives accelerated FDA approval for the treatment of R/R mantle cell lymphoma

The Food and Drug Administration (FDA) granted accelerated approval to pirtobrutinib for the treatment of relapsed/refractory (R/R) mantle cell lymphoma…

Zanubrutinib receives FDA approval for the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma

Zanubrutinib was approved by the Food and Drug Administration (FDA) on the 19th of January 2023, for the treatment of…

ASH late-breaking abstract rundown

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

ASH press briefing rundown: changing the status quo for blood cancers

VJHemOnc is thrilled to bring you the latest updates from the 64th American Society of Hematology (ASH) Annual Meeting and…

Biological therapy in NHL: treating with CAR-T versus BiTEs

VJHemOnc is pleased to bring you a feature exploring the latest developments in the treatment of NHL, with leading experts…

Highlights from the 2022 Third Annual Texas MPN Workshop (TMW)

VJHemOnc is excited to bring you the latest updates from the 2022 third annual Texas MPN Workshop, which brought together…

Teclistamab receives EMA approval for adult patients with relapsed/refractory (R/R) multiple myeloma

On August 24 2022, the European Medicines Agency (EMA) approved the use of teclistamab for the treatment of patients with…

Betibeglogene autotemcel receives FDA approval for patients with transfusion-dependent β-thalassemia

On August 17 2022, the US Food and Drug Administration (FDA) approved the first cell-based gene therapy, betibeglogene autotemcel (beti-cel),…

TKI therapy in CP-CML: toxicity management & approaching a cure

VJHemOnc is pleased to bring you a feature covering the current state of the field in the treatment CP-CML with…

Highlights in lymphoid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in lymphoid malignancies from the EHA 2022 Congress, which took…

Highlights in myeloid malignancies from EHA 2022

VJHemOnc is excited to bring you the latest research updates in myeloid malignancies from the EHA 2022 Congress, which took…

DETERMINATION: the addition of ASCT to lenalidomide, bortezomib, and dexamethasone provides a PFS advantage for patients with newly diagnosed multiple myeloma

For decades, autologous stem cell transplants (ASCTs) with high-dose chemotherapy has been the standard of care for patients with newly…

features: Trial Updates